跳至主要内容
临床试验/TCTR20201102001
TCTR20201102001招募中2 期

A topical eye drop versus intra-meibomian gland injection of bevacizumab for meibomian gland dysfunction patients.

Ratchadapiseksompotch Fund0 个研究点目标入组 30 人开始时间: 2020年11月2日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 80 Years(—)
性别
All

入选标准

  • • Age 18-80 years
  • • Symptoms ≥ 1: dryness, FB sensation, burning, tearing & duration > 6 months
  • • Diagnosis of MGD stage 2 or 3 with lid margin telangiectasia grade 2 or 3 both eyes
  • • Willingness to regular follow-up as appointed

排除标准

  • • Ocular structure abnormality
  • • History of ocular trauma, ocular and other surgery
  • • Use of any treatment for DED or MGD except artificial tears within the past month
  • • Active allergy, infection, inflammation at ocular surface unrelated to DE, MGD
  • • History of ocular herpes infection
  • • Lacrimal gland drainage system abnormality
  • • Contact Lens wear within the past month
  • • Use systemic medication affecting the ocular surface,systemic anti-inflammatory medication, anticoagulant or antiplatelet medication
  • • Unstable systemic diseases: uncontrolled HT, uncontrolled DM, stroke, coronary artery disease, cerebrovascular disease, bleeding diathesis
  • • History of bevacizumab contra-indication: congestive heart failure, GI perforation,
  • pregnancy, breast feeding, reversible posterior leukoencephalopathy syndrome (RPLS),
  • proteinuria, surgery and wound healing complications
  • • Allergy to bevacizumab, moxifloxacin

研究者

发起方
Ratchadapiseksompotch Fund

相似试验